Results 81 to 90 of about 27,540 (239)

Gut microbiota as a novel therapeutic target for eating disorders and obesity

open access: yesBritish Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė   +5 more
wiley   +1 more source

Anticipatory pleasure predicts effective connectivity in the mesolimbic system

open access: yes, 2015
Convergent evidence suggests the important role of the mesolimbic pathway in anticipating monetary rewards. However, the underlying mechanism of how the sub-regions interact with each other is still not clearly understood.
Zeng, Ya-Wei   +7 more
core  

Hypocretin/orexin regulation of dopamine signaling: implications for reward and reinforcement mechanisms

open access: yesFrontiers in Behavioral Neuroscience, 2012
The hypocretins/orexins are comprised of two neuroexcitatory peptides that are synthesized exclusively within a circumscribed region of the lateral hypothalamus.
Rodrigo eEspaña, Erin S Calipari
doaj   +1 more source

The ongoing oleoylethanolamide story: Therapeutic implications in the control of obesity and its comorbidities

open access: yesBritish Journal of Pharmacology, EarlyView.
The global burden of obesity continues to rise, demanding effective pharmacological strategies for individuals in whom prevention alone is insufficient. Recent incretin‐based and multi‐agonist therapies have delivered unprecedented weight loss, demonstrating that the simultaneous modulation of multiple metabolic pathways can optimize body weight ...
Marzia Friuli   +6 more
wiley   +1 more source

The dual incretin agonist tirzepatide blunts nicotine‐induced behaviours and neurochemistry in male mice

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Nicotine dependence remains one of the leading causes of morbidity and mortality worldwide, with high relapse rates and post‐cessation weight gain representing persistent barriers to sustained abstinence. The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) have ...
Christian E. Edvardsson   +5 more
wiley   +1 more source

Effects of lifelong sulforaphane intake on behavioural, neurochemical and biomolecular dysfunctions in the BTBR T+ Itpr3tf/J mouse model of autism spectrum disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Created in BioRender. Schiavone, S. (2026). https://BioRender.com/cy0xq6z. Abstract Background and Purpose Autism spectrum disorders (ASD) are multifactorial neurodevelopmental conditions associated with oxidative stress and neuroinflammation across critical developmental periods.
Vladyslav Sikora   +8 more
wiley   +1 more source

Acetaldehyde sequestering prevents ethanol-induced stimulation of mesolimbic dopamine transmission

open access: yes, 2009
Acetaldehyde (ACD) has been postulated to mediate some of the neurobehavioral effects of ethanol (EtOH). In this study we sought to evaluate whether the stimulatory effects of EtOH on mesolimbic dopamine (DA) transmission are affected by the ...
Mereu, Maddalena   +13 more
core   +2 more sources

Stress as a Risk Factor for Substance Use Disorders: A Mini-Review of Molecular Mediators

open access: yesFrontiers in Behavioral Neuroscience, 2018
The extant literature supports the role of stress in enhancing the susceptibility of drug abuse progressing to a substance use disorder diagnosis. However, the molecular mediators by which stress enhances the progression from cocaine abuse to cocaine use
Deepika Mukhara   +2 more
doaj   +1 more source

The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review

open access: yesClinical Obesity, Volume 15, Issue 2, April 2025.
Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy